Jacobson Mark L., COO, reported a transaction classified as grant at Axsome Therapeutics, Inc. involving 10769.000000 shares for an estimated $0.00. Reported holdings after the transaction were 10769.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Operating Officer
The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested o…
Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.
Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date.
0 other filings
0 recent txs